Immunohistochemical comparison of three programmed death-ligand 1 (PD-L1) assays in triple-negative breast cancer.
<h4>Background</h4>Triple-negative breast cancer (TNBC) is the most aggressive type of breast cancer. A recent study demonstrated the efficacy of anti-PD-L1 (anti-programmed death ligand-1) immunotherapy in patients with TNBC. However, the identification of TNBC patients who may benefit...
Enregistré dans:
Auteurs principaux: | , , , , , |
---|---|
Format: | article |
Langue: | EN |
Publié: |
Public Library of Science (PLoS)
2021
|
Sujets: | |
Accès en ligne: | https://doaj.org/article/0312115e02ca406ba35c64337ec308fd |
Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|